The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Dow Jones Top Company Headlines at 9 PM ET: UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud | Dick’s ... UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud ...

From 2015 and 2021, almost 30% of deaths among residents and fellows were due to suicide. In other news: Medicare fraud at UnitedHealth; patient fall rates at rehab facilities; and more.

Correctional officers often dictate end-of-life care for incarcerated people who are terminally ill. Most states either don’t have a formal policy or are given leeway — a big concern for families and ...

Novo Nordisk has reported new data with its long-acting human growth hormone (hGH) product Sogroya, showing it is at least as effective as its older drug Norditropin in various paediatric growth ...

A clinical-stage biotech company developing targeted therapeutics for rare neurodevelopmental disorders. The company’s lead ...

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...